FMP
REGENXBIO Inc.
RGNX
NASDAQ
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
5.39 USD
-0.025 (-0.464%)
Mr. Curran M. Simpson M.S.
Healthcare
Biotechnology
NASDAQ
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
0001590877
US75901B1070
75901B107
9804 Medical Center Drive
240 552 8181
US
353
Sep 17, 2015
Craig Malzahn
Executive Vice President, Product Develo...
0
N/A
Dr. Ram Palanki Pharm.D.
Executive Vice President of Commercial S...
0
1977
Mr. Mitchell Chan M.B.A.
Executive Vice President & Chief Financi...
0
1981
Mr. Patrick J. Christmas II, J.D.
Executive Vice President & Chief Legal O...
1.11M
1971
Ms. Shiva G. Fritsch
Chief Communications & People Officer
0
N/A
Dr. Olivier Danos Ph.D.
Executive Vice President & Chief Scienti...
778.85k
1958
Mr. Curran M. Simpson M.S.
President, Chief Executive Officer & Dir...
698.6k
1962
Dr. Stephen Pakola M.D.
Executive Vice President & Chief Medical...
674.05k
1969
As of December 31, 2024, the total employee count stands at 353, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.